Cancer Research Articles

A variety of drugs are used to treat cancer. Delivered by infusions, injections, or taken orally, it takes a range of specially trained professionals working together to ensure that these pharmaceuticals are used safely and effectively so that patients achieve optimal clinical outcomes.   

The sports world is mourning the loss of Jim Corsi who passed away after a battle with liver and colon cancer.

While everyone should aim to eat healthy, cancer survivors in particular must make healthy, selective choices when preparing a meal. It is crucial to support the body, which continues to heal post-treatment.

Florida Cancer Specialists & Research Institute, LLC (FCS) medical oncologist Gail Lynn Shaw Wright, MD, FACP, FCCP is co-author of a Phase II study that examined the efficacy of administering Trilaciclib prior to chemotherapy in patients with metastatic triple-negative breast cancer.

Physicians from FCS presented studies on blood cancer research at the American Society of Hematology Annual Meeting and Exposition.

The inaugural Metastatic Breast Cancer Heroes™ winners were announced by CURE Media Group, recognizing individuals making a difference in the lives of those affected by metastatic breast cancer.  Among the three winners is Florida Cancer Specialists & Research Institute, LLC (FCS) oncology nurse Brandi Riber, RN, based in Fort Myers.

Medical oncologist Manish R Patel, MD, a member of the clinical research team at Florida Cancer Specialists & Research Institute , LLC (FCS), first-authored a study examining dose escalation of an oral complete estrogen receptor (ER) antagonist (CERAN)/selective ER degrader (SERD) in cases of advanced and/or metastatic estrogen receptor-positive, HER2-negative breast cancer.

Medical oncologist James Reeves, MD, a member of the clinical research team at Florida Cancer Specialists & Research Institute (FCS), is co-author of a study that examined the use and effectiveness of niraparib, a targeted therapy drug, to reduce the recurrence of HER2-negative, BRCA mutated breast cancer. Entitled, “Correlation Between Presence of Circulating Tumor DNA and Response to Neoadjuvant Niraparib in HER2-Negative, BRCA-Mutated Breast Cancer,” the study will be shared in a poster presentation at the San Antonio Breast Cancer Symposium being held Dec. 7 – 12, 2021.